BioVie Inc. has fully enrolled its Phase 2 ADDRESS-LC trial to test bezisterim, a drug candidate aimed at treating neurological symptoms of Long COVID such as brain fog and fatigue. The trial, funded by a $13.13 million grant from the U.S. Department of War, involves about 200 patients and compares bezisterim against a placebo to assess improvements in cognitive function and fatigue. This milestone is significant as there are currently no FDA-approved treatments for Long COVID neurological symptoms. Topline results are expected in late summer 2026, potentially offering a new therapeutic option for millions affected by Long COVID.
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
